The Experts below are selected from a list of 60 Experts worldwide ranked by ideXlab platform

Fakhrul Ahsan - One of the best experts on this subject based on the ideXlab platform.

  • Newer devices and improved formulations of inhaled Insulin
    Expert opinion on drug delivery, 2014
    Co-Authors: Jahidur Rashid, Shahriar Absar, Kamrun Nahar, Nilesh Gupta, Fakhrul Ahsan
    Abstract:

    Introduction: Delivery of therapeutic Insulin via the pulmonary route has been the most investigated non-invasive alternative to the commonly used subcutaneous (SC) route for diabetes management. Despite discontinuation of the first Inhalable Insulin, Exubera®, due to suboptimal market acceptance, development of orally inhaled Insulin delivery systems has been galvanized by the recent approval of Afrezza® and several others awaiting approval.Areas covered: The scope of this review article includes the prospects for and the challenges faced in developing inhaled Insulin delivery systems; discussion of orally inhaled therapeutic Insulin delivery systems that were discontinued, recently approved or are currently under active investigation; and formulation approaches that have the potential to deliver Insulin via the pulmonary route.Expert opinion: The pulmonary route is the most advantageous route for non-invasive Insulin delivery. Inhalable Insulin therapeutics have the potential to be successful, provided ...

Weng Jian-ping - One of the best experts on this subject based on the ideXlab platform.

  • Multicenter clinical study on the efficacy and safety of Inhalable Insulin aerosol in the treatment of type 2 diabetes
    Chinese Medical Journal, 2008
    Co-Authors: Liao Zhi-hong, Chen Ying-li, Li Fang-ping, Yan Xiang, Lu Hai, Zhou Zhi-guang, Zhu Da-long, Ji Li-nong, Weng Jian-ping
    Abstract:

    Background A new Inhalable Insulin aerosol (Inh-Ins) was developed in China. The aim of this multicenter clinical study was to evaluate the efficacy and safety of this new Inh-Ins as a treatment of type 2 diabetes. Regular porcine Insulin (RI) was used as a control. Methods This study is a prospective, randomized, open-label, parallel-group multicenter clinical trial in which 253 qualified patients with type 2 diabetes received the Insulin Glargine daily at bedtime plus either a pre-meal Inh-Ins or a pre-meal subcutaneous RI for 12 weeks. HbA1c, fasting plasma glucose (FPG), the 1-hour-postprandial blood glucose (1hPBG) and the 2-hour-postprandial blood glucose (2hPBG) were measured. Events were monitored for adverse effects. Results After 12 weeks, the HbA1c decreased significantly from baseline in both treatment groups, with no significant difference between the two regimens. In the Inh-Ins group, FPG, both 1hPBG and 2hPBG significantly declined from baseline after the 8th- and 12th-weeks of treatment. The reduced values of FPG or ihPBG between the two groups showed a more significant hypoglycemic effect with the Inh-Ins than the RI. After 12 weeks, the pulmonary carbon monoxide diffusing capacity (DLco) was significantly lower in Inh-Ins group than in the RI. The main side effects of Inh-Ins were coughing, excessive sputum, and hypoglycemia. Conclusions Inh-Ins was effective in decreasing HbA1c like the RI. It was better in lowering the FPG and the 1hPBG than the RI. Its main side effects were coughing, excessive sputum, and hypoglycemia. Also, Inh-Ins slightly impaired DLco.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000257699700002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=8e1609b174ce4e31116a60747a720701Medicine, General & InternalSCI(E)中国科技核心期刊(ISTIC)1ARTICLE131159-116412

Jianping Weng - One of the best experts on this subject based on the ideXlab platform.

  • multicenter clinical study on the efficacy and safety of Inhalable Insulin aerosol in the treatment of type 2 diabetes
    Chinese Medical Journal, 2008
    Co-Authors: Zhihong Liao, Yingli Chen, Xiang Yan, Li Yan, Zhiguang Zhou, Dalong Zhu, Jianping Weng
    Abstract:

    BACKGROUND A new Inhalable Insulin aerosol (Inh-Ins) was developed in China. The aim of this multicenter clinical study was to evaluate the efficacy and safety of this new Inh-Ins as a treatment of type 2 diabetes. Regular porcine Insulin (RI) was used as a control. METHODS This study is a prospective, randomized, open-label, parallel-group multicenter clinical trial in which 253 qualified patients with type 2 diabetes received the Insulin Glargine daily at bedtime plus either a pre-meal Inh-Ins or a pre-meal subcutaneous RI for 12 weeks. HbA1c, fasting plasma glucose (FPG), the 1-hour-postprandial blood glucose (1hPBG) and the 2-hour-postprandial blood glucose (2hPBG) were measured. Events were monitored for adverse effects. RESULTS After 12 weeks, the HbA1c decreased significantly from baseline in both treatment groups, with no significant difference between the two regimens. In the Inh-Ins group, FPG, both 1hPBG and 2hPBG significantly declined from baseline after the 8th- and 12th-weeks of treatment. The reduced values of FPG or 1hPBG between the two groups showed a more significant hypoglycemic effect with the Inh-Ins than the RI. After 12 weeks, the pulmonary carbon monoxide diffusing capacity (DLco) was significantly lower in Inh-Ins group than in the RI. The main side effects of Inh-Ins were coughing, excessive sputum, and hypoglycemia. CONCLUSIONS Inh-Ins was effective in decreasing HbA1c like the RI. It was better in lowering the FPG and the 1hPBG than the RI. Its main side effects were coughing, excessive sputum, and hypoglycemia. Also, Inh-Ins slightly impaired DLco.

Jahidur Rashid - One of the best experts on this subject based on the ideXlab platform.

  • Newer devices and improved formulations of inhaled Insulin
    Expert opinion on drug delivery, 2014
    Co-Authors: Jahidur Rashid, Shahriar Absar, Kamrun Nahar, Nilesh Gupta, Fakhrul Ahsan
    Abstract:

    Introduction: Delivery of therapeutic Insulin via the pulmonary route has been the most investigated non-invasive alternative to the commonly used subcutaneous (SC) route for diabetes management. Despite discontinuation of the first Inhalable Insulin, Exubera®, due to suboptimal market acceptance, development of orally inhaled Insulin delivery systems has been galvanized by the recent approval of Afrezza® and several others awaiting approval.Areas covered: The scope of this review article includes the prospects for and the challenges faced in developing inhaled Insulin delivery systems; discussion of orally inhaled therapeutic Insulin delivery systems that were discontinued, recently approved or are currently under active investigation; and formulation approaches that have the potential to deliver Insulin via the pulmonary route.Expert opinion: The pulmonary route is the most advantageous route for non-invasive Insulin delivery. Inhalable Insulin therapeutics have the potential to be successful, provided ...

Linda Wang - One of the best experts on this subject based on the ideXlab platform.

  • a sweet start for Inhalable Insulin
    Chemical & Engineering News, 2006
    Co-Authors: Linda Wang
    Abstract:

    EVER SINCE Insulin WAS DISCOVered some 85 years ago, researchers have been searching for needle-free ways to deliver the hormone to people who have diabetes. They've looked at oral delivery, nasal delivery, and even dermal delivery using a patch. Now, the first of these noninvasive approaches, Inhalable Insulin, is about to reach the market after approval in late January by the U.S. Food & Drug Administration and the European Medicines Evaluation Agency. The product, marketed by Pfizer under the trade name Exubera, is expected to be available to consumers by midsummer. "It's a historic event," says Tarun K. Mandal, a professor of pharmaceutics at Xavier University of Louisiana, in New Orleans. Not only will Inhalable Insulin offer people with diabetes more options to control their disease, it also sets a precedent for other drugs to be delivered systemically through the lungs, he points out. According to the American Diabetes Association, ...